• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Who made 100% in MS Division

Quote
















Anonymous said:
It might be tough but you will get different experience for your resume. Talk to the Genzyme people. Their leadership understands MS is a specialty market not primary care.I will try to leave just for the culture that understands how to treat the customers. Did you know Aubagio new prescriptions are almost the same as Gilenya? Scary how bad Gilenya is doing
Click to expand...

Yes yes

please leave

Aubagio has stabilized at a mighty 2.4% market share and a price about half og Gilenya's...surely you have a bright future at Genzyme...good luck with lemtrada

baggle pushers
 




Anonymous said:
Yes yes

please leave

Aubagio has stabilized at a mighty 2.4% market share and a price about half og Gilenya's...surely you have a bright future at Genzyme...good luck with lemtrada

baggle pushers
Click to expand...


YOU'RE RIGHT. AUBAGIO MARKETSHARE IS PREDICTED TO BE LESS THAN GILENYA.

GILENYA 6% BY NOVEMBER 2013 AND TECFIDERA 15%. HAHAHAHAHAHAHAHAHAHAHA



U.S. Neurologists Have Prescribed Biogen Idec's Tecfidera, the Third-to-Market Oral Therapy, to Their Multiple Sclerosis Patients
Tecfidera's High Early Physician Trial Rate Surpasses that Observed With Novartis's Gilenya and Genzyme's Aubagio, According to a New Report from BioTrends Research Group



EXTON, Pa., July 11, 2013 /PRNewswire via COMTEX/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, despite being the third oral disease-modifying therapy (DMT) to launch in the U.S. multiple sclerosis (MS) market, 53 percent of surveyed U.S. neurologists have prescribed Biogen Idec's Tecfidera to at least one of their MS patients after only one month on the market. This rate for Tecfidera surpasses that for Novartis's Gilenya (19 percent), the first-to-market oral DMT, and Genzyme's Aubagio (16 percent), the second-to-market oral DMT, at the same stage of product launch. Data from the recently published LaunchTrends: Tecfidera Wave 1 report suggest that this impressive physician trial rate is likely to continue to grow over the coming months, with nearly all surveyed neurologists anticipating at least some Tecfidera prescribing among their DMT-treated relapsing-remitting MS (RRMS) patients over the next six months. Coupled with this expansion in prescriber base, Tecfidera patient share among DMT-treated RRMS patients is anticipated to increase significantly from 2 percent to 15 percent, beating that projected for Aubagio (4 percent) and Gilenya (6 percent) by November 2013.




Given the previous dominance of injectable DMTs in the MS market, it is not surprising that neurologists identify Tecfidera's oral formulation as being one of its main advantages, similar to the attitudes observed with the launches of Aubagio and Gilenya. However, the report finds that early Tecfidera trial and uptake may be driven more by neurologists' comfort with Tecfidera's safety profile and positive efficacy perceptions--together with the low monitoring burden required with Tecfidera treatment, especially compared to other oral DMTs--than by its mode of administration.

Nonetheless, the report also reveals that the upward trend in Tecfidera prescribing may be hampered by managed care issues, with neurologists recalling that up to one-quarter of Tecfidera prescriptions required proof of failure on a previous DMT despite Tecfidera's label not including any line restrictions. During qualitative interviews, a subset of Tecfidera prescribers expressed frustration in the time taken for patients to receive Tecfidera, with neurologists suggesting that delays may be due, in part, to preauthorization requirements with managed care companies.

"Given neurologists' hesitancy to switch patients who are responding well to their current DMT, potential managed care issues, and anticipated stable treatment rates, the projected increase in Tecfidera trial and adoption may end up being somewhat more muted," said BioTrends Research Group Analyst Emma Williams, Ph.D. "However, even if neurologists' conservative prescribing patterns blunt some of the trajectory, uptake will most likely still drive Tecfidera into a market leading position among oral DMTs by the end of 2013."

About BioTrends Research GroupBioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources GroupDecision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.
 




Anonymous said:
Yes yes

please leave

Aubagio has stabilized at a mighty 2.4% market share and a price about half og Gilenya's...surely you have a bright future at Genzyme...good luck with lemtrada

baggle pushers
Click to expand...

what the hell is a baggle?

fool. if you are going to insult a whole sales force, at least try and spell the offending word correctly
 




Anonymous said:
Yes yes

please leave

Aubagio has stabilized at a mighty 2.4% market share and a price about half og Gilenya's...surely you have a bright future at Genzyme...good luck with lemtrada

baggle pushers
Click to expand...


For baggle pushers that want to jump to Genzyme: most phone screens are done, over half of F2Fs are done to select you for a hub city cattle call round robin interview day. Offers by end of August hopefully.
 








Wow! The pressure is on....SRF's are low. If they only knew that current SRF daily totals are inflated due to nurses in certain areas resubmitting canceled cases just to pad the numbers and make themselve look good.
 




Love my primary care manager trying to tell me how to sell a MS drug... Oh that's right, she sold Diovan........laughable at best. Go do a spread sheet tracker and stay out of my offices....bimbo!
 




If it wasnt for excel spreadsheets and conference calls, these fuckin RD's and ABL's wouldnt know what to do. Waiting for the day I have to send a spreadsheet for how many times a take a shit.
 
























Anonymous said:
I got a verbal. It's true!!
Click to expand...

Thanks you for leaving

Have lots of fun at sanofi ...keep calling it Genzyme if it makes you feel better

Happy to see you leave as obviously our top 20% are staying put because they are paid, recognized and have constant interation with senior managers and HR setting them up for future opportunities...or at least are getting tons of smoke blown up their asses making em feel special

the other 80% of you mediocre or sub par players...we are happy if at least half of you leave...

A lateral transfer is the hallmark of mediocre talent BTW...every pharma hiring manager knows this...
 




Anonymous said:
Thanks you for leaving

Have lots of fun at sanofi ...keep calling it Genzyme if it makes you feel better

Happy to see you leave as obviously our top 20% are staying put because they are paid, recognized and have constant interation with senior managers and HR setting them up for future opportunities...or at least are getting tons of smoke blown up their asses making em feel special

the other 80% of you mediocre or sub par players...we are happy if at least half of you leave...

A lateral transfer is the hallmark of mediocre talent BTW...every pharma hiring manager knows this...
Click to expand...

Amen! Perfectly said!
 








Top Bottom
Back
Quote